News Focus
News Focus
Followers 42
Posts 776
Boards Moderated 0
Alias Born 01/17/2022

Re: sentiment_stocks post# 439706

Saturday, 01/29/2022 9:44:29 PM

Saturday, January 29, 2022 9:44:29 PM

Post# of 818036
Yes, I agree, if both n and rGBM are supported by the trial data, which makes sense based on the n and rGBM tumor profiles (pre and post mutation) shared in multiple publications and all of the LL commentary, DCVax-L could be a sizable opportunity for GBM. The only question is whether DCVax-L can impact patients sufficiently without resections upon progression.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News